Cardiovascular Response to Adrenergic Stimulation during Treatment with Tertatolol

A New Non-Cardioselective Beta-Blocking Agent in Primary Hypertensive Patients

Abstract

The antihypertensive effects of tertatolol, a new non-cardioselective beta-blocking drug, were investigated in 20 patients with mild to moderate primary arterial hypertension, in a placebo controlled double blind randomized study, After tertatolol 5mg o.d. significant decreases in both systolic and diastolic blood pressure and in heart rate were observed at rest (BP from 155/103±3/1 to 139/91±4/3mmHg p<0.01; HR from 79±2 to 60±2bpm p<0.01). Peak blood pressure, heart rate and myocardial O₂ consumption, indirectly measured as cardiac workload, determined during adrenergic stimulation by 70° head-up tilt, cold pressor test, mental arithmetic stress, isometric exercise and bicycle exercise were also reduced by 4 weeks of tertatolol treatment in comparison to pretreatment levels. No significant changes in the same parameters were induced by placebo. No side effects were observed during treatment.